Effect of a single dose of oral azithromycin on malaria parasitaemia in children: a randomized controlled trial.
Azithromycin
Burkina Faso
Malaria
Randomized controlled trial
Journal
Malaria journal
ISSN: 1475-2875
Titre abrégé: Malar J
Pays: England
ID NLM: 101139802
Informations de publication
Date de publication:
31 Aug 2021
31 Aug 2021
Historique:
received:
09
03
2021
accepted:
25
08
2021
entrez:
1
9
2021
pubmed:
2
9
2021
medline:
5
11
2021
Statut:
epublish
Résumé
Azithromycin has recently been shown to reduce all-cause childhood mortality in sub-Saharan Africa. One potential mechanism of this effect is via the anti-malarial effect of azithromycin, which may help treat or prevent malaria infection. This study evaluated short- and longer-term effects of azithromycin on malaria outcomes in children. Children aged 8 days to 59 months were randomized in a 1:1 fashion to a single oral dose of azithromycin (20 mg/kg) or matching placebo. Children were evaluated for malaria via thin and thick smear and rapid diagnostic test (for those with tympanic temperature ≥ 37.5 °C) at baseline and 14 days and 6 months after treatment. Malaria outcomes in children receiving azithromycin versus placebo were compared at each follow-up timepoint separately. Of 450 children enrolled, 230 were randomized to azithromycin and 220 to placebo. Children were a median of 26 months and 51% were female, and 17% were positive for malaria parasitaemia at baseline. There was no evidence of a difference in malaria parasitaemia at 14 days or 6 months after treatment. In the azithromycin arm, 20% of children were positive for parasitaemia at 14 days compared to 17% in the placebo arm (P = 0.43) and 7.6% vs. 5.6% in the azithromycin compared to placebo arms at 6 months (P = 0.47). Azithromycin did not affect malaria outcomes in this study, possibly due to the individually randomized nature of the trial. Trial registration This study is registered at clinicaltrials.gov (NCT03676751; registered 19 September 2018).
Sections du résumé
BACKGROUND
BACKGROUND
Azithromycin has recently been shown to reduce all-cause childhood mortality in sub-Saharan Africa. One potential mechanism of this effect is via the anti-malarial effect of azithromycin, which may help treat or prevent malaria infection. This study evaluated short- and longer-term effects of azithromycin on malaria outcomes in children.
METHODS
METHODS
Children aged 8 days to 59 months were randomized in a 1:1 fashion to a single oral dose of azithromycin (20 mg/kg) or matching placebo. Children were evaluated for malaria via thin and thick smear and rapid diagnostic test (for those with tympanic temperature ≥ 37.5 °C) at baseline and 14 days and 6 months after treatment. Malaria outcomes in children receiving azithromycin versus placebo were compared at each follow-up timepoint separately.
RESULTS
RESULTS
Of 450 children enrolled, 230 were randomized to azithromycin and 220 to placebo. Children were a median of 26 months and 51% were female, and 17% were positive for malaria parasitaemia at baseline. There was no evidence of a difference in malaria parasitaemia at 14 days or 6 months after treatment. In the azithromycin arm, 20% of children were positive for parasitaemia at 14 days compared to 17% in the placebo arm (P = 0.43) and 7.6% vs. 5.6% in the azithromycin compared to placebo arms at 6 months (P = 0.47).
CONCLUSIONS
CONCLUSIONS
Azithromycin did not affect malaria outcomes in this study, possibly due to the individually randomized nature of the trial. Trial registration This study is registered at clinicaltrials.gov (NCT03676751; registered 19 September 2018).
Identifiants
pubmed: 34465327
doi: 10.1186/s12936-021-03895-9
pii: 10.1186/s12936-021-03895-9
pmc: PMC8407066
doi:
Substances chimiques
Antimalarials
0
Azithromycin
83905-01-5
Banques de données
ClinicalTrials.gov
['NCT03676751']
Types de publication
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
360Subventions
Organisme : Bill and Melinda Gates Foundation
ID : OPP1187628
Organisme : Research to Prevent Blindness
ID : Research to Prevent Blindness
Informations de copyright
© 2021. The Author(s).
Références
N Engl J Med. 2018 Apr 26;378(17):1583-1592
pubmed: 29694816
J Biol Chem. 2007 Jan 26;282(4):2494-504
pubmed: 17110371
PLoS One. 2016 Jun 21;11(6):e0157045
pubmed: 27326859
PLoS Med. 2019 Jun 25;16(6):e1002835
pubmed: 31237871
PLoS One. 2016 Nov 18;11(11):e0165692
pubmed: 27861509
Malar J. 2019 Dec 3;18(1):389
pubmed: 31796025
PLoS One. 2021 Jan 8;16(1):e0244284
pubmed: 33417600
Clin Infect Dis. 1998 Jan;26(1):146-50
pubmed: 9455524
Invest Ophthalmol Vis Sci. 2003 Apr;44(4):1464-9
pubmed: 12657580
Am J Trop Med Hyg. 2016 Jul 6;95(1):2-4
pubmed: 27215296
N Engl J Med. 2019 Jun 06;380(23):2197-2206
pubmed: 30699301
Br J Clin Pharmacol. 2016 Jul;82(1):199-212
pubmed: 26889763
PLoS Med. 2020 Mar 23;17(3):e1003055
pubmed: 32203504
Clin Infect Dis. 2021 Jan 08;:
pubmed: 33417683
Glob Health Action. 2010 Sep 14;3:
pubmed: 20847837
Malar J. 2015 Mar 10;14:108
pubmed: 25881046
Am J Trop Med Hyg. 2020 Dec 21;:
pubmed: 33350370
Pediatr Infect Dis J. 2018 Jun;37(6):506-510
pubmed: 29088030
Malar J. 2015 Aug 05;14:300
pubmed: 26243295
Cochrane Database Syst Rev. 2011 Feb 16;(2):CD006688
pubmed: 21328286
Trans R Soc Trop Med Hyg. 2005 Jan;99(1):6-12
pubmed: 15550255
Am J Trop Med Hyg. 2017 Sep;97(3):696-701
pubmed: 28722569
Lancet Glob Health. 2020 Feb;8(2):e288-e295
pubmed: 31981558
Antimicrob Agents Chemother. 2007 Oct;51(10):3485-90
pubmed: 17698630
Am J Trop Med Hyg. 2014 May;90(5):846-51
pubmed: 24615132
Res Rep Trop Med. 2017 Oct 13;8:85-104
pubmed: 30050349